Drug Profile


Alternative Names: BGC 9331; ZD 9331

Latest Information Update: 06 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; BTG; Cancer Research UK Centre for Cancer Therapeutics
  • Developer BTG
  • Class Antineoplastics; Tetrazoles
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Gastric cancer
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gastric cancer; Ovarian cancer; Pancreatic cancer
  • Discontinued Colorectal cancer; Solid tumours

Most Recent Events

  • 06 Dec 2010 No development reported - Phase-I/II for Gastric cancer in Europe (IV-infusion)
  • 06 Dec 2010 No development reported - Phase-II for Gastric cancer in Czech Republic (IV-infusion)
  • 06 Dec 2010 No development reported - Phase-II for Gastric cancer in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top